Cencora reports Q4 adjusted EPS $3.84, consensus $3.79

Reports Q4 revenue $83.7B, consensus $83.39B. “Cencora (COR) furthered key initiatives in fiscal 2025 to fortify our leading position in healthcare, most notably by enhancing our position in specialty through our acquisition of RCA as well as the decision to strategically refocus our existing business portfolio,” said Bob Mauch, President and Chief Executive Officer of Cencora. “Our strategic drivers of prioritizing growth-oriented investments, accelerating digital transformation, cultivating a best-in-class team member culture, and enabling productivity position Cencora to drive value for our stakeholders. As we move into fiscal 2026, we are catalyzing growth and innovation, with our purpose at the core of all we do,” Mr. Mauch continued. “Our increased long-term guidance reflects our confidence that Cencora’s foundation in pharmaceutical distribution and leading capabilities, coupled with our focused execution will continue driving growth well into the future.”